Selexis and Merrimack agree R&D accord

11 June 2006

Swiss biotechnology firm Selexis SA, a specialist developer of cell lines used in the production of therapeutic proteins, says it has signed a non-exclusive R&D deal with Merrimack Pharmaceuticals.

Under the terms of the deal, Merrimack, which is based in Massachusettes, USA, gains the rights to use Selexis' SURE technology platform, specifically in the development of mammalian cells lines. Financial terms of the agreement were not revealed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight